12Saccharomyces boulardii is a widely used yeast probiotic which can counteract various 13 gastrointestinal disorders 1 . As a relative of Saccharomyces cerevisiae, S. boulardii exhibits rapid 14 growth and is easy to transform 2 and thus represents a promising chassis for the engineered 15 secretion of biomolecules. To establish S. boulardii as a platform for delivery of biomolecules to 16 the mammalian gut, we measured the amount and variance in protein expression enabled by 17 promoters, terminators, selective markers, and copy number control elements in this organism. 18These genetic elements were characterized in plasmidic and genomic contexts, revealing 19 strategies for tunable control of gene expression and CRISPR-mediated genome editing in this 20 strain. We then leveraged this set of genetic parts to combinatorially assemble pathways 21 enabling a wide range of drug and vitamin titers. Finally, we measured S. boulardii's residence 22 time in the gastrointestinal tracts of germ-free and antibiotic-treated mice, revealing the 23 relationships between dosing strategy and colonization level. This work establishes S. boulardii 24 as a genetically tractable commensal fungus and provides a set of strategies for engineering S. 25 boulardii to synthesize and deliver biomolecules during gut colonization. 26 27 abundant in the human gut, 21 and difficulty in producing high levels of post-translationally-42 modified proteins 22 . 43
44In addition to bacteria, a diverse fungal population also exists in the human gastrointestinal tract 45 (GIT) [23][24][25][26] . While the numerical abundance of fungal cells in the GIT is much lower than bacterial 46 cells, fungal cells are on average 100-fold larger, indicating that their biomass and role in the gut 47 may be larger than metagenomic surveys indicate 25,27 . Recent studies have shown that while 48 3 commensal fungi play important roles in the development of inflammatory bowel diseases, they 49 also provide protective heterologous immunity to pathogenic organisms by training the immune 50 system 28,29 . Furthermore, fungi are not susceptible to bacteriophage predation and are easily 51 engineered to secrete high titers of proteins that are post-translationally modified. Thus, in this 52 study, we established a pipeline to engineer the only eukaryotic probiotic that is approved by the 53 FDA: Saccharomyces boulardii 30 . 54 55 S. boulardii is a non-pathogenic yeast that was originally isolated from lychee and mangosteen in 56 1923 and has since been used to treat ulcerative colitis, diarrhea, and recurrent Clostridium 57 difficile infection 1,31 . S. boulardii is closely related to the famous budding yeast Saccharomyces 58 cerevisiae, indicating that it may be similarly amenable to engineering for the production of 59 biomolecules, including biologics requiring post-translational modifications 2,32 . Supporting this, 60 S. cerevisiae expression vectors can be transformed and propagated in S. boulardii, and 61 CRISPR/Cas9-mediated genome editing is functional in both ...